

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

POSITIVE PROFIT ALERT

This announcement is made by OrbusNeich Medical Group Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the information currently available to the Board, for the six months ended June 30, 2023 (the “**Current Period**”), the Group is expected to record (i) an increase in profit for the period attributable to owners of the Company by over 200% as compared with that for the six months ended June 30, 2022 (the “**Previous Period**”); and (ii) an increase in adjusted profit for the period (non-HKFRS measure^{Note}) by over 100% as compared with that for the Previous Period.

The increase in profit for the period attributable to owners of the Company is mainly attributable to the following factors: (i) increase in gross profit arising from the increase in sales of the Group’s balloons; (ii) increase in interest income from bank deposits; and (iii) listing expenses did not recur for the Current Period as the listing of the Company was completed in 2022.

Note: Adjusted profit for the period (non-HKFRS measure) is calculated by excluding the effect of listing expenses, unwinding of interests on convertible redeemable preferred shares and share-based compensation expenses.

As the Company is still in the process of finalizing the unaudited interim results of the Group for the Current Period, the information contained in this announcement is only based on a preliminary assessment by the Board of the information currently available and has not been audited or reviewed by the Company's auditor or the audit committee of the Company. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group which is expected to be released in August 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN
Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 31, 2023

As at the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU, Mr. Wing Shing CHEN and Mr. Ching Chung John CHOW as Executive Directors; Dr. Yi ZHOU and Mr. Ting San Peter Lionel LEUNG as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.